0.3999

14.75% 0.0514

After Hours: .36 -0.0399 -9.98%

Ensysce Biosciences Inc (ENSC)

Overview News Price History Financials Discussions Forecast Stock Split

Ensysce Biosciences Inc stock is traded at $0.3999, with a volume of 18.25M. It is up +14.75% in the last 24 hours and up +36.72% over the past month. Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Previous Close:

$0.3485

Open:

$0.3391

24h Volume:

18.25M

Relative Volume:

1.41

Market Cap:

$6.14M

Revenue:

$4.71M

Net Income/Loss:

$-11.79M

P/E Ratio:

-0.1194

EPS:

-3.3492

Net Cash Flow:

$-9.72M

1W Performance:

-23.13%

1M Performance:

+36.72%

6M Performance:

-8.07%

1Y Performance:

-80.59%

1-Day Range:

$0.3306

$0.4745

1-Week Range:

$0.3306

$0.505

52-Week Range:

$0.23

$2.75

Ensysce Biosciences Inc Stock (ENSC) Company Profile

Name

Ensysce Biosciences Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(858) 263-4196

Address

7946 IVANHOE AVENUE, LA JOLLA

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

ENSC's Discussions on Twitter

Compare ENSC vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENSC Ensysce Biosciences Inc	0.3999	6.13M	4.71M	-11.79M	-9.72M	-3.3492
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Ensysce Biosciences Inc Stock (ENSC) Latest News

Aug 14, 2026

Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma

Aug 14, 2026

Ensysce Completes Cy Biopharma Acquisition Adding Lead CRPS Candidate - Minichart

Aug 14, 2026

Aug 13, 2026

Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com - Investing.com Australia

Aug 13, 2026

Ensysce Q2 Results: EPS beats estimate, sales up 16% vs view - scanx.trade

Aug 13, 2026

Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal - Stock Titan

Aug 13, 2026

Ensysce Biosciences Q2 net loss widens on higher R&D costs - TradingView

Aug 13, 2026

ENSC: Acquisition and new funding extend cash runway, with clinical pipeline and losses both increasing - TradingView

Aug 13, 2026

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - FinancialContent

Aug 13, 2026

Aug 11, 2026

Cy Biopharma merges with Ensysce Biosciences - Startupticker.ch

Aug 11, 2026

Aug 10, 2026

Ensysce Biosciences (ENSC) officer reports 154.8M underlying common via preferred - Stock Titan

Aug 10, 2026

Aug 07, 2026

Ensysce Biosciences Acquires Cy Biopharma to Expand Pain Pipeline - sekbernews.id

Aug 07, 2026

Ensysce Biosciences Inc (NASDAQ: ENSC) Share Price, ENSC Stock News, ENSC Share Price & Updates - Kalkine

Aug 07, 2026

Orrick Advises Cy Biopharma on Acquisition by Ensysce Biosciences and up to $77 Million Private Financing - orrick.com

Aug 07, 2026

Ensysce Biosciences Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView

Aug 07, 2026

Form 8K Ensysce Biosciences Inc For: 6 August By Investing.com - Investing.com South Africa

Aug 07, 2026

ENSC|Ensysce Biosciences Inc|Price:0.520|Chg%:-0.004 - TradingKey

Aug 07, 2026

Aug 06, 2026

Ensysce completes Cy Biopharma acquisition, raises $21.5 million By Investing.com - Investing.com Australia

Aug 06, 2026

Ensysce Biosciences Acquires Cy Biopharma in Deal Backed by Up to $77 Million Financing - citybiz

Aug 06, 2026

Ensysce expands into neuroplastogenic pain with USD 77m Cy Biopharma acquisition - AllSci

Aug 06, 2026

Ensysce Biosciences Surges After Cy Biopharma Acquisition and Large Financing Package - Quiver Quantitative

Aug 06, 2026

Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing - Yahoo Finance

Aug 06, 2026

Ensysce completes Cy Biopharma acquisition, raises $21.5 million - Investing.com

Aug 06, 2026

Ensysce Acquires Cy Biopharma, Expands Pain Therapy Portfolio - TipRanks

Aug 06, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Aug 06, 2026

Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings - Sahm

Aug 06, 2026

Aug 04, 2026

The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch - Barchart.com

Aug 04, 2026

Ensysce Biosciences (NASDAQ:ENSC) surges 48%, still faces 141% climb for Nasdaq $1 threshold - TechStock²

Aug 04, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Aug 04, 2026

Why is Ensysce Biosciences stock surging today? By Investing.com - Investing.com Canada

Aug 04, 2026

Why is Ensysce Biosciences stock surging today? - Investing.com

Aug 04, 2026

Aug 03, 2026

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Aug 03, 2026

Aug 02, 2026

Ensysce lands $5.3M grant, completing $15.1M NIDA opioid-safety award - Dealroom

Aug 02, 2026

Jul 31, 2026